TSVT - 2seventy bio posts Phase 1 results for CAR-T therapy in bone marrow cancer

2023-05-19 07:01:26 ET

Cell and gene therapy company 2seventy bio, Inc. ( NASDAQ: TSVT ) on Friday announced results from its ongoing Phase 1 trial for CD33-targeting chimeric antigen receptor (CAR) T cell therapy, SC-DARIC33 in patients with bone marrow cancer acute myeloid leukemia.

According to the company, the trial named PLAT-08 for pediatric and young adults with relapsed or refractory AML indicated no dose-limiting toxicities for SC-DARIC33 following lymphodepletion (LD) chemotherapy.

As of March 17, 2023, the study drug had also been well tolerated after patients received 1 x 106 SC-DARIC33 T cells /kg following LD chemotherapy.

The trial, a collaboration between 2seventy bio ( TSVT ) and Seattle Children’s Therapeutics, is designed to assess the safety and toxicity of SC-DARIC33, as well as the feasibility of its production.

After LD, the patients received SC-DARIC33 T cells followed by rapamycin to activate SC-DARIC33.

“These data reinforce the potential of SC-DARIC333 as a new T cell therapy approach in AML,” Chief Medical Officer of TSVT Steven Bernstein remarked.

More on 2seventy bio

• Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expanded use
• 2seventy Bio: KarMMa-3 Finally Releases Positive Results

For further details see: